Mineralys Therapeutics Announced Sunday, Phase 3 Transform-HTN Extension Data For Lorundrostat, Showing Sustained 17.8 mmHg Systolic BP Reduction At Week 48, 56% Achieving BP Below 130 mmHg
Share
Why It Matters
Mineralys tested a new blood pressure medicine on patients for a long time. More than half of patients got their blood pressure down to a healthy level.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.